Juran Kato, Ph.D.
President and CEO, Founder

  • Molecular Biology
  • Pharma R&D experience in drug repositioning and oncology
  • Executive training in MIT Sloan School of Management
  • AACR female scholar award recipient

Appointments/Education：
2017  Associate Director, Innovation and Entrepreneurship
Takeda Pharmaceutical Company Limited
2012  Associate Director, Extra Value Generation Drug Discovery Unit
Takeda Pharmaceutical Company Limited
2006  Principal Scientist Oncology Drug Discovery Unit
Takeda Pharmaceutical Company Limited
2000  Assistant Researcher, Postdoctoral fellow
University of California, Los Angeles
2000  Ph.D. (Molecular Biology), Tokyo Institute of Technology
1996  Lecturer, International Christian University

Honor/Awards：
Drug Discovery Unit Head Award, Research Division Head Award, Department Head Award (Takeda Pharmaceutical Company Limited)
Brigid G. Leventhal Scholars in Cancer Research Award for the promising female researcher (AACR)

Patent：
1 substance patent
1 utility patent

Selected publications：
1) Signal Transduction Second Edition (article in Japanese) Ed Y. Kaziro and Satoh (2011) MDSi
2) Career path 101 for PhDs in Bioscience Majors (article in Japanese) Ed. Miura and Sengoku (2009) Yodosha

Mami Ojima
Director & CKO, Co-Founder

  • Track record of INDs of Candesartan, ARBs, ACEi and PPAR agonist, etc.
  • Pharma presidential award

Appointments/Education：
2017  Principal Scientist, Innovation and Entrepreneurship
Takeda Pharmaceutical Company Limited
1997  Principal Scientist, Cardiovascular and Metabolic Diseases Drug Discovery Unit
Takeda Pharmaceutical Company Limited
1980  Research Scientist, Cardiovascular Diseases Pharmacology Unit
Takeda Pharmaceutical Company Limited
1980  College of Medical Technology,Kyoto University

Honor/Awards：
Takeda Global Award, Pharmacology Department Head Award, 1989 President Award (Takeda Pharmaceutical Company Limited)

Patent：
More than 1 substance and utility patent

Selected publications:
1) Ojima et al., 2011, J Pharmacol Exp Ther.
2) Ojima et al., 1997, Eur J Pharmacol.
3) Ojima et al., 1996, Jpn Pharmacol Ther.

Lili Mao, PhD
CSO, Co-Founder

  • Biochemistry
  • Project leader for drug repositioning
  • Extensive experience in project management of CRO operation
  • Inventor of technology patents

Appointments/Education：
2017  Principal Scientist, Innovation and Entrepreneurship
Takeda Pharmaceutical Company Limited
2015  Postdoctoral Fellow, Extra Value Generation Drug Discovery Unit
Takeda Pharmaceutical Company Limited
2012  Postdoctoral Associate, University of Minnesota
2010  Research Associate, Postdoctoral Fellow, Rutgers University
2010  Ph.D. (Biochemistry) University of Medicine and Dentistry of New Jersey

Honor/Awards：
2011, 2010, Technical Highlight, PSI/Nature Structural Biology Knowledgebase

Patent：
2 Technological inventions

Selected publications:
1) Mao et al., 2013, Encyclopedia of Biophysics
2) Mao et al., 2012, Methods in Molecular Biology
3) Mao et al., 2010, J. Struct Funct Genomics
4) Hosomi et al., 2018, An integrative approach using real-world data to identify alternative  therapeutic uses of existing drugs, Plos ONE

Takako Naito, RPh
Research Alliance, Chief,
Co-Founder

  • Track record of INDs including Cefozopran, Ceftaroline, etc.
  • Expertise in multiple disease areas